FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 200116.403D1	APPLICATION NO. 09/982,315
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		APPLICANTS Horst Fisher and Beate Illek	
		FILING DATE October 17, 2001	GROUP ART UNIT 1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,639,661	06/17/97	Welsh and Sheppard	435	252.3	
	AB	5,972,995	10/26/99	Fischer et al.	514	456	
	AC	6,329,422 B1	12/11/01	Fischer et al.	514	456	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	AD	WO 99/18953	04/22/99	WIPO		

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AE		Abstract of JP 62-053923, Derwent WPI Acc. No. 87-105816, March 9, 1987.
	AF		Abstract of JP 05-236910, Derwent WPI Acc. No. 93-330545, September 17, 1993.
	AG		Abstract of JP 07-059548, Derwent WPI Acc. No. 95-135875, March 7, 1995.
	AH		Abstract of RU 2,008,015, Derwent WPI Acc. No. 94-277493, February 28, 1994.
	AI		Anderson et al., "Generation of cAMP-Activated Chloride Currents by Expression of CFTR," *Science 251*: 679-682, February 8,1991.
	AJ		Brown et al., "Chemical chaperones correct the mutant phenotype of the ΔF508 cystic fibrosis transmembrane conductance regulator protein," *Cell Stress & Chaperones 1*(2): 117-125, 1996.
	AK		Hwang et al., "Genistein potentiates wild-type and ΔF508-CFTR channel activity," *American Journal of Physiology 273*(3, part 1): C988-C998, 1997.
	AL		Illek et al., "cAMP-independent activation of CFTR C1 channels by the tyrosine kinase inhibitor genistein," *American Journal of Physiology 268*(4 part 1): C886-C893, 1995.
	AM		Knowles et al., "*In Vivo* Nasal Potential Difference: Techniques and Protocols for Assessing Efficacy of Gene Transfer in Cystic Fibrosis," *Human Gene Therapy 6*: 445-455, April 1995.
	AN		Riordan et al., "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA," *Science 245*: 1066-1073, September 8, 1989.
	AO		Rubenstein et al., "In Vitro Pharmacologic Restoration of CFTR-mediated Chloride Transport with Sodium 4-Phenylbutyrate in Cystic Fibrosis Epithelial Cells," *J. Clin. Invest. 100*(10): 2457-2465, November 1997.

EXAMINER	DATE CONSIDERED
Howard Flaxman	6/24/04

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 200116.403D1	APPLICATION NO. 09/982,315
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		APPLICANTS Horst Fisher and Beate Illek	
		FILING DATE October 17, 2001	GROUP ART UNIT 1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	BJ					
	BK					
	BL					
	BM					
	BN					

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

HV	BO		Scott and Cooperstein, "Ascorbic acid stimulates chloride transport in the amphibian cornea," *Investigative Ophthalmology 14*(10): 763-766, October 1975.
HV	BP		Sheppard et al., "Mutations in CFTR associated with mild-disease-form Cl^- channels with altered pore properties," *Nature 362*: 160-164, March 11, 1993.
HV	BQ		Smith, "Treatment of cystic fibrosis based on understanding CFTR," *J. Inher. Metab. Dis. 18*: 508-516, 1995.

EXAMINER Howard Crews	DATE CONSIDERED 6/24/04

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).